Granules India is currently trading at Rs. 136.10, up by 3.00 points or 2.25% from its previous closing of Rs. 133.10 on the BSE.
The scrip opened at Rs. 138.00 and has touched a high and low of Rs. 138.70 and Rs. 135.30 respectively. So far 2,00,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 164.45 on 01-Dec-2015 and a 52 week low of Rs. 75.55 on 12-Jun-2015.
Last one week high and low of the scrip stood at Rs. 138.70 and Rs. 126.60 respectively. The current market cap of the company is Rs. 2,852.00 crore.
The promoters holding in the company stood at 51.15% while Institutions and Non-Institutions held 7.59% and 41.26% respectively.
Granules India has received an approval of further investment of $17.07 million by way of debt/equity in Granules Pharmaceutical Inc., a wholly owned foreign subsidiary of the company. The board of directors at its meeting held on April 28, 2016 has approved for the same.
The board has also approved further investment of Rs 50 crore by way of debt/equity in GIL Lifescienses, a wholly owned Indian subsidiary.
Granules India produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.05 |
Dr. Reddys Lab | 1354.20 |
Cipla | 1470.05 |
Lupin | 2190.50 |
Zydus Lifesciences | 1004.05 |
View more.. |